Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $312.22

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average rating of “Moderate Buy” from the twelve research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $321.55.

Several research analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Oppenheimer lifted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. UBS Group increased their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. TD Cowen lifted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $326.35, for a total transaction of $1,174,860.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $42,425.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the sale, the director now owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $326.35, for a total transaction of $1,174,860.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,425.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,884 shares of company stock worth $27,931,991. 12.50% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC boosted its position in United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after acquiring an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in shares of United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after purchasing an additional 33,338 shares during the period. Nordea Investment Management AB grew its position in United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after purchasing an additional 23,532 shares in the last quarter. BNP Paribas Financial Markets increased its stake in United Therapeutics by 90.3% in the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after buying an additional 26,325 shares during the period. Finally, Duality Advisers LP lifted its position in United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after buying an additional 5,622 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.8 %

NASDAQ:UTHR opened at $321.38 on Monday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average of $290.04 and a 200-day moving average of $250.19. The firm has a market capitalization of $14.26 billion, a PE ratio of 15.20, a price-to-earnings-growth ratio of 1.40 and a beta of 0.55. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $330.00.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period last year, the company earned $4.86 earnings per share. Analysts predict that United Therapeutics will post 24.85 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.